Management remains confident of exceeding its earlier financial year 2026 guidance of Rs 335 crore in revenue and Rs 100 crore in net profit
Driven by continued demand strength and smooth operational execution, Cupid, a manufacturer and exporter of condoms and other products, has stated that it expects the third quarter of the current financial year (Q3FY26) to be the company’s best quarter so far.
In a regulatory filing, the company noted that order book stands at its highest level so far, providing clear visibility for performance in the coming quarters. Management remains confident of exceeding its earlier FY26 guidance of Rs 335 crore in revenue and Rs 100 crore in net profit (Pat), supported by operating efficiencies, stable demand and execution progress.
“We begin 2026 with encouraging momentum, strong order visibility, and steady progress across our expansion initiatives. The in-principle approval for the proposed Saudi FMCG facility reflects our intent to gradually build a broader and more diversified growth platform, while remaining focused on prudent capital allocation. We remain confident of surpassing our FY26 guidance,” stated Aditya Kumar Halwasiya, Chairman and Managing Director.
The company pointed out that its fast-moving consumer goods (FMCG) portfolio continues to see growing demand across India, supported by expanding retail presence in the personal care and wellness categories. Recently introduced products such as petroleum jelly, face wash and talcum Powder have received encouraging consumer response.
As part of its long-term strategy, Cupid is gradually strengthening its presence in the GCC region, with a focus on improving supply responsiveness and market proximity. Following the Board’s in-principle approval notified on 29 December 2025, the proposed FMCG manufacturing facility in the Kingdom of Saudi Arabia is intended to support regional demand and improve supply timelines across the GCC and nearby export markets.
The project is targeted for completion by March 2027, subject to regulatory approvals and execution milestones. Cupid’s investment in GII Healthcare Investment Fund has appreciated to approximately 1.2-times of the initial investment made in October 2025, the company stated.
